Compositions and methods for delivery of photosensitive drugs

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,455,858
App. No.: 10/440,505
Granted: Nov 25, 2008
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention provides nanoparticles containing photosensitizers and their use in the field of photodynamic therapy (PDT). The invention also provides methods for the preparation of such nanoparticles as well as for their sterilization.

Claims (19)

1. A photosensitizer-loaded nanoparticle comprising one or more green porphyrins and one or more polymers of poly(D,L-lactide-co-glycolide), poly(D,L-lactide), or a combination thereof, wherein the porphyrin is rapidly released from the nanoparticle upon introduction into a serum-containing environment.

2. The nanoparticle of claim 1 , wherein said one or more green porphyrins is selected from BPD-MA, QLT 0074 or QLT 0069.

3. The nanoparticle of claim 1 wherein the polymer is poly(D,L-lactide).

4. The nanoparticle of claim 1 wherein the polymer is poly(D,L-lactide-co-glycolide).

5. The nanoparticle of claim 1 having a mean diameter of less than 200 nm.

6. The nanoparticle of claim 1 having a mean diameter of between 100 and 200 nm.

7. The nanoparticle of claim 1 additionally comprising a lyoprotectant.

8. The nanoparticle of claim 7 , wherein the lyoprotectant is trehalose.

9. The nanoparticle of claim 1 in a freeze dried form.

10. The nanoparticle of claim 1 , wherein the green porphyrins comprise from about 1% to about 20% by weight of the nanoparticle.

11. The nanoparticle of claim 10 wherein the green porphyrins comprises from about 5 to about 10% by weight of the nanoparticle.

12. The nanoparticle of claim 1 , wherein the nanoparticles release at least 50% of the porphyrin within one minute of contacting a serum-containing medium.

13. The nanoparticle of claim 12 wherein the serum-containing medium is a bodily fluid of an animal.

14. The nanoparticle of claim 13 wherein the serum-containing medium is human blood.

15. The nanoparticle of claim 13 having a mean particle size of less than 200 nm in diameter.

16. The nanoparticle of claim 13 wherein the mean particle size is between about 100 nm and 200 nm in diameter.

17. A composition comprising the nanoparticle of claim 1 .

18. The nanoparticle of claim 1 having a mean diameter of about 200 nm.

19. The nanoparticle of claim 13 having a mean particle size of about 200 nm in diameter.

Assignments (21)

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED

Reel/Frame 073637/0001 →

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.

Reel/Frame 073637/0222 →

ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (065709/0253) Recorded Aug 14, 2025

From: CITIBANK, N.A., AS RESIGNING AGENT

To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT

Reel/Frame 072460/0691 →

RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025

From: BARCLAYS BANK PLC, AS COLLATERAL AGENT

To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.

Reel/Frame 070778/0199 →

OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Apr 17, 2024

From: THE BANK OF NEW YORK MELLON